Attovia Therapeutics, Inc. (ATTO) News
Follow Attovia Therapeutics, Inc. (ATTO) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 16 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026
SAN CARLOS, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia”) NASDAQ:ATTO, a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated disease
NEWS | Sep 28, 2026, 08:08 PM UTC
L
ATTO - Attovia Therapeutics to Participate in Upcoming Investor Conferences
ATTO - Attovia Therapeutics to Participate in Upcoming Investor Conferences
EQUITY | Sep 03, 2026, 08:08 PM UTC
L
Attovia Therapeutics Reports Second Quarter 2026 Financial Results And Provides A Corporate Update
Attovia Therapeutics Inc NASDAQ:ATTO
EARNINGS | Sep 02, 2026, 08:47 PM UTC
M
ATTO net loss $39.3M in 1H 2026; IPO funds runway to 2030
ATTO reported net loss of $39.3 million for the first half of 2026, driven by a 40% rise in R&D expenses. The company’s August 2026 IPO raised $305.4 million in net proceeds, extending its cash runway into 2030.
EQUITY | Sep 02, 2026, 08:25 PM UTC
L
Attovia posts Q2 2026 revenue and net loss; cash into 2030
Attovia reported Q2 2026 collaboration revenue of $0.5 million and a net loss of $20.7 million. It ended June 30, 2026 with $115.1 million in cash, cash equivalents and marketable securities, expecting IPO proceeds to ex
EARNINGS | Sep 02, 2026, 08:24 PM UTC
L
Attovia Therapeutics upsizes IPO proceeds to $332.4M
Attovia Therapeutics upsized IPO proceeds to $332.4 million to extend its cash runway into 2030.
EQUITY | Sep 02, 2026, 08:08 PM UTC
L
Attovia Therapeutics 2Q revenue $450,000
Attovia Therapeutics reported 2Q revenue of $450,000 for ATTO.
EQUITY | Sep 02, 2026, 08:07 PM UTC
L
ATTO - Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
ATTO - Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
EARNINGS | Sep 02, 2026, 08:06 PM UTC
L
Attovia Therapeutics 2Q Loss/Shr $4.88 >ATTO
Attovia Therapeutics 2Q Loss/Shr $4.88 >ATTO
EQUITY | Sep 02, 2026, 08:06 PM UTC
M
Attovia Therapeutics posts $20.7M 2Q loss
Attovia Therapeutics reported a $20.7M loss in 2Q.
EQUITY | Sep 02, 2026, 08:05 PM UTC
L
Attovia Therapeutics initiated at Buy by Citigroup
Citigroup initiated Attovia Therapeutics at Buy, according to TradingView News.
EQUITY | Aug 31, 2026, 03:15 PM UTC
L
Attovia Therapeutics price target set at $45.00 by LifeSci Capital
LifeSci Capital announced a $45.00 per share price target for Attovia Therapeutics.
EQUITY | Aug 31, 2026, 02:43 PM UTC
L
Attovia Therapeutics Initiated at Outperform by Leerink Partners
Attovia Therapeutics Initiated at Outperform by Leerink Partners
EQUITY | Aug 31, 2026, 02:39 PM UTC
M
Attovia Therapeutics Debuts on Nasdaq
Attovia Therapeutics starts trading on Nasdaq
EQUITY | Aug 06, 2026, 09:58 AM UTC
M
Attovia Therapeutics Prices Upsized IPO
Attovia Therapeutics prices upsized initial public offering
EQUITY | Aug 05, 2026, 12:50 AM UTC
L
ATTO - Attovia, an early-stage drug developer focused on immune-mediated diseases with high unmet need, is seeking to raise as much as $212.
ATTO - Attovia, an early-stage drug developer focused on immune-mediated diseases with high unmet need, is seeking to raise as much as $212.5M in a US IPO
EQUITY | Jul 30, 2026, 01:27 AM UTC